Here's an opportunity in PGNX folks! Down 4% on some news from a competitor ADLR~ they updated their timeline for a product that treats constipation like PGNX's does~ it's a race to toilet bowl nirvana in stock land. How quickly we forget the good vibe after PGNX's recent earnings. 4Q Results Thursday March 15, NEW YORK (AP) -- Shares of drug developer Progenics Pharmaceuticals Inc. rose Thursday after the company said it narrowed its fourth-quarter loss on a jump in reimbursement for research and development activities. The stock rose $1.16 cents, or 5.1 percent, to close at $23.76 on the Nasdaq Stock Market. The company reported a fourth-quarter loss narrower than Wall Street expected. Revenue jumped to $21.9 million from $2 million from a partnership with Wyeth over oral methylnaltrexone, a treatment for constipation caused by pain medication. Piper Jaffray analyst Caroline Stewart reaffirmed an "Outperform" rating with a $28 price target, citing the company's fourth-quarter revenue and cash position. "The company ended the year with $149 million in cash and equivalents, in our view enough to support operations through the launch of all three planned formulations of lead candidate methylnaltrexone," she wrote in a note to investors. RBC Capital Markets analyst Michael Yee reaffirmed a "Outperform" rating with a $35 price target, citing positive expectations for the company. "We continue to believe Progenics is at an important juncture as partner Wyeth reiterated its expectation to file a new drug application for methylnaltrexone this quarter," Yee wrote. "If a Priority Review is granted, approval could come in the third quarter." Citigroup analyst Dr. Yaron Werber reaffirmed a "Buy" rating with a $33 price target, citing a positive outlook for the company's product pipeline. >> I'll shout out to the hedge fund monday to see if they are still in it- was a fave'. & I'll have some info on the other player in this great race- ADLR.